
1. j travel med. 2019 dec 23;26(8). pii: taz077. doi: 10.1093/jtm/taz077.

dengue, zika chikungunya pregnancy: pre- post-travel advice and
clinical management.

vouga m(1), chiu yc(1), pomar l(1), de meyer sv(1), masmejan s(1), genton b(2),
musso d(3), baud d(1), stojanov m(1).

author information: 
(1)materno-fetal obstetrics research unit, department woman-mother-child,
lausanne university hospital (chuv), lausanne, switzerland.
(2)travel medicine, lausanne university hospital (chuv), lausanne, switzerland.
(3)aix marseille university, ird, ap-hm, ssa, vitrome, ihu-méditerranée
infection, marseille, france.

rationale review: young adults childbearing age pregnant women are
travelling frequently tropical areas, exposing specific arboviral
infections dengue, zika chikungunya viruses, may impact ongoing
and future pregnancies. narrative review, analyse potential
consequences pregnancy outcomes discuss current travel recommendations.
main findings: dengue virus may associated severe maternal complications,
particularly post-partum haemorrhage. association adverse fetal outcomes
remains unclear, prematurity, growth retardation stillbirths may occur,
particularly cases severe maternal infection. zika virus teratogenic
infectious agent associated severe brain lesions, similar risks to
other well-known torch pathogens. implications chikungunya virus pregnancy 
are mostly related intrapartum transmission may associated severe
neonatal infections long-term morbidity.
travel recommendations: agencies provide specific travel recommendations 
travelling pregnant patients couples trying conceive discrepancies
exist, particularly regarding zika virus prevention. risks significantly
depend epidemiological factors may difficult predict. prevention
relies principally mosquito control measures. couples trying conceive and
pregnant women receive adequate information potential risks. 
seems reasonable advise pregnant women avoid unnecessary travel aedes
spp. endemic regions. current rationale avoid travel delay conception 
is debatable absence epidemic. post-travel laboratory testing
should reserved symptomatic patients.

© international society travel medicine 2019. rights reserved. for
permissions, please e-mail: journals.permissions@oup.com.

doi: 10.1093/jtm/taz077 
pmcid: pmc6927317
pmid: 31616923  [indexed medline]

